NAGIOS: RODERIC FUNCIONANDO

Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis

Mostra el registre parcial de l'element

dc.contributor.author Simpione, Guilherme es
dc.contributor.author Caldas, Rogério J. es
dc.contributor.author Soares, Mariana Quirino Silveira es
dc.contributor.author Rubira Bullen, Izabel Regina Fischer es
dc.contributor.author Santos, Paulo Sergio da Silva es
dc.date.accessioned 2020-10-22T11:50:33Z
dc.date.available 2020-10-22T11:50:33Z
dc.date.issued 2020 es
dc.identifier.citation Simpione, Guilherme ; Caldas, Rogério J. ; Soares, Mariana Quirino Silveira ; Rubira Bullen, Izabel Regina Fischer ; Santos, Paulo Sergio da Silva. Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis. En: Journal of Clinical and Experimental Dentistry, 12 3 2020: 285-290 es
dc.identifier.uri https://hdl.handle.net/10550/76019
dc.description.abstract Bisphosphonates (BP) are synthetic pyrophosphate-like substances with antiresorptive properties and specifically affect osteoclastic activity. In 2007, the American Association of Oral and Maxillofacial Surgeons (AAOMS) defined diagnostic criteria for Osteonecrosis of the Jaws Associated with Bisphosponates (BRONJ). BRONJ is mainly diagnosed by clinical features, but the detection of early bone changes by imaging may help prevent and better understand the disease. The objective of this study was to evaluate maxillary changes in CBCT in patients using BP. All included patients were diagnosed with osteonecrosis and received bisphosphonate drugs in the last ten years. All imaging examinations were obtained by I-CAT and 3D Accuitomo. The multiplanar reconstructions were analyzed by an examiner without knowledge of the clinical aspects and location of the lesions. The study sample consisted of 21 patients, the majority of the sample represented patients with cancer (76.2%), the other patients had osteoporosis (23.8%). Only four patients (19.04%) received alendronate, while intravenous bisphosphonates, such as zoledronate and pamidronate, represented the treatment of most of our sample. Most of our patients presented stage 1 and 2 MRONJ (85.7%), whose lesions were mainly observed in the mandible (52.4%). Fifty-seven percent of the patients had at least one bone change. In BRONJ, bone changes vary between exposed and non-exposed areas and one aspect of the study was: persistent extraction cavities in the BRONJ lesion region and high frequency of periodontal ligament space widening in areas that are not involved in BRONJ lesions. This reflects the very important role of dental and periodontal diseases in the pathophysiology of BRONJ. Thus, preventive measures should be prioritized for patients exposed to anti-resorptive drugs. es
dc.title Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis es
dc.type journal article es_ES
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.identifier.doi 10.4317/jced.56265 es
dc.type.hasVersion VoR es_ES

Visualització       (327.5Kb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques